ArticleNature communications2021

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.

Cristina Valero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.